Federal Register / Vol. 71, No.
62 / Friday, March 31, 2006 / Rules and Regulations
these three combination drug medicated
feeds.
The NADAs are approved as of
February 15, 2006, and the regulations
are amended in 21 CFR 558.76, 558.78,
558.369, and 558.680 to reflect the
approval. Approval of these
supplemental NADAs did not require
review of any new safety or
effectiveness data. Therefore, a freedom
of information summary was not
prepared.
The agency has determined under 21
CFR 25.33(a)(2) that these actions are of
a type that do not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
Zoalene in grams/ton Combination in grams/ton
(i) * * *
Bacitracin 4 to 50
Bacitracin methylene disa-
licylate 4 to 50 plus
roxarsone 22.7 to 45.4
* *
* * * * * DEPARTMENT OF HEALTH AND
Dated: March 22, 2006.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 06–3122 Filed 3–30–06; 8:45 am]
BILLING CODE 4160–01–S
hsrobinson on PROD1PC61 with RULES
VerDate Aug<31>2005 14:51 Mar 30, 2006 Jkt 208001
16223
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
■ Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 558 is amended as follows:
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
■ 1. The authority citation for 21 CFR
part 558 continues to read as follows:
Authority: 21 U.S.C. 360b, 371.
§ 558.76 [Amended]
■ 2. In § 558.76, amend paragraph
(d)(3)(xviii) by adding ‘‘or roxarsone’’
after ‘‘arsanilic acid’’.
■ 3. In § 558.78, amend paragraph (d)(3)
by redesignating paragraphs (d)(3)(x)
through (d)(3)(xii) as paragraphs
(d)(3)(xi) through (d)(3)(xiii); and add
new paragraph (d)(3)(x) to read as
follows:
Indications for use
Replacement chickens: For development
of active immunity to coccidiosis; for in-
creased rate of weight gain, improved
feed efficiency
Replacement chickens: For development
of active immunity to coccidiosis; for in-
creased rate of weight gain, improved
feed efficiency, and improved pigmenta-
tion
* * * *
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 558
[Docket No. 2003N–0324]
New Animal Drugs for Use in Animal
Feeds; Bacitracin; Nicarbazin;
Oxytetracycline and Neomycin;
Penicillin
AGENCY: Food and Drug Administration,
HHS.
ACTION: Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of four supplemental new
animal drug applications (NADAs) filed
PO 00000 Frm 00031 Fmt 4700 Sfmt 4700 E:\FR\FM\31MRR1.SGM
§ 558.78 Bacitracin zinc.
* * * * *
(d) * * *
(3) * * *
(x) Nitarsone as in § 558.369.
* * * * *
§ 558.369 [Amended]
■ 4. In § 558.369, amend paragraph
(d)(2)(i) by adding ‘‘or bacitracin zinc’’
after ‘‘disalicylate’’.
■ 5. In § 558.680, amend the table in
paragraph (d)(1)(i), after the entry for
‘‘Arsanilic acid 90 (0.01%) plus
penicillin 2.4 to 50’’ by adding entries
for ‘‘Bacitracin 4 to 50’’ and ‘‘Bacitracin
methylene disalicylate 4 to 50 plus
roxarsone 22.7 to 45.4’’ to read as
follows:
§ 558.680 Zoalene.
* * * * *
(d) * * *
(1) * * *
Limitations
Feed as in subtable in § 558.680(d)(1)(i);
grower ration not to be fed to birds over
14 weeks of age. As bacitracin meth-
ylene disalicylate provided by No.
046573 in § 510.600(c) of this chapter
Feed as in subtable in § 558.680(d)(1)(i);
grower ration not to be fed to birds over
14 weeks of age. Discontinue use 5
days before slaughter; as sole source
of organic arsenic; drug overdose or
lack of water may result in leg weak-
ness. As bacitracin methylene disalicy-
late and roxarsone provided by No.
046573 in § 510.600(c) of this chapter
*
by Phibro Animal Health. One
supplemental NADA provides for the
use of fixed-combination Type A
medicated articles containing
oxytetracycline and neomycin sulfate to
formulate two-way fixed-combination
drug Type B and Type C medicated
feeds for chickens, turkeys, swine,
cattle, and sheep. Two of the
supplemental NADAs provide for the
use of approved, single-ingredient Type
A medicated articles containing
nicarbazin and penicillin, with or
without roxarsone, to formulate two-
way or three-way combination drug
Type C medicated feeds for broiler
chickens. The fourth supplemental
NADA provides for the use of approved,
single-ingredient Type A medicated
articles nicarbazin, bacitracin methylene
disalicylate, and roxarsone to formulate
three-way combination drug Type C
31MRR1
 16224 Federal Register / Vol. 71, No. 62 / Friday, March 31, 2006 / Rules and Regulations
medicated feeds for broiler chickens.
These approvals reflect FDA’s
effectiveness conclusions which relied
on the National Academy of Sciences/
National Research Council (NAS/NRC)
Drug Efficacy Study Group’s evaluation
of the effectiveness of these drugs when
used in animal feed as single
ingredients.
DATES: This rule is effective March 31,
2006.
FOR FURTHER INFORMATION CONTACT:
Andrew J. Beaulieu, Center for
Veterinary Medicine (HFV–50), 7519
Standish Pl., Rockville, MD 20855, 240–
276–9090, e-mail:
andrew.beaulieu@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of August 8, 2003 (68
FR 47332), as corrected October 7, 2003
(68 FR 57919), as part of the Drug
Efficacy Study Implementation (DESI)
program, CVM announced the effective
conditions of use for several drug
products and use combinations listed in
21 CFR 558.15. CVM proposed to
withdraw the new animal drug
applications (NADAs) for those
products or use combinations lacking
substantial evidence of effectiveness
following a 90-day opportunity to
supplement the NADAs with labeling
conforming to the relevant findings of
effectiveness. Phibro Animal Health, 65
Challenger Rd., 3d Floor, Ridgefield
Park, NJ 07660, filed supplements to
four of its approved NADAs to revise
the labeling of its products to comply
with these findings of effectiveness.
Phibro Animal Health filed a
supplement to approved NADA 94–975
for NEO–TM 50/50D and NEO–TM 100/
100D (oxytetracycline and neomycin
sulfate) Type A medicated articles. The
supplemental NADA provides for use of
these fixed-combination Type A
medicated articles to formulate two-way
fixed-combination drug Type B and
Type C medicated feeds containing
oxytetracycline and neomycin sulfate,
in a 1:1 ratio, for several production and
therapeutic indications in chickens,
turkeys, swine, cattle, and sheep.
Phibro Animal Health also filed a
supplement to approved NADA 98–371
for use of nicarbazin, procaine
penicillin, and roxarsone single-
ingredient Type A medicated articles to
make three-way combination drug Type
C medicated feeds. This supplemental
NADA provides for the use of
combination feeds containing
hsrobinson on PROD1PC61 with RULES
NICARBAZIN (nicarbazin) at 90.8 to
181.6 grams per ton (g/ton), PENICILLIN
VerDate Aug<31>2005 14:51 Mar 30, 2006 Jkt 208001
G PROCAINE (procaine penicillin) at
2.4 to 50 g/ton, and 3–NITRO
(roxarsone) at 22.7 to 45.4 g/ton of feed
in broiler chickens as an aid in
preventing outbreaks of cecal (Eimeria
tenella) and intestinal (E. acervulina, E.
maxima, E. necatrix, and E. brunetti)
coccidiosis; for increased rate of weight
gain and improved feed efficiency; and
for improved pigmentation.
Phibro Animal Health also filed a
supplement to approved NADA 98–374
for use of nicarbazin and procaine
penicillin G Type A medicated articles
to formulate two-way combination drug
Type C medicated feeds. This
supplemental NADA provides for the
use of combination feeds containing
NICARBAZIN (nicarbazin) at 90.8 to
181.6 g/ton and PENICILLIN G
PROCAINE (procaine penicillin) at 2.4
to 50 g/ton of feed in broiler chickens
as an aid in preventing outbreaks of
cecal (Eimeria tenella) and intestinal (E.
acervulina, E. maxima, E. necatrix, and
E. brunetti) coccidiosis; and for
increased rate of weight gain and
improved feed efficiency.
Phibro Animal Health also filed a
supplement to approved NADA 100–
853 for use of nicarbazin, bacitracin
methylene disalicylate, and roxarsone
single-ingredient Type A medicated
articles to make three-way combination
drug Type C medicated feeds. This
supplemental NADA provides for the
use of combination feeds containing
NICARBAZIN (nicarbazin) at 90.8 to
181.6 g/ton, BMD (bacitracin methylene
disalicylate) at 4 to 50 g/ton, and 3–
NITRO (roxarsone) at 22.7 to 45.4 g/ton
of feed in broiler chickens as an aid in
preventing outbreaks of cecal (Eimeria
tenella) and intestinal (E. acervulina, E.
maxima, E. necatrix, and E. brunetti)
coccidiosis, and for increased rate of
weight gain, improved feed efficiency,
and improved pigmentation.
The DESI evaluation is concerned
only with the effectiveness of the drug
products and use combinations. Nothing
in this document constitutes a bar to
further proceedings with respect to
questions of safety of the subject drugs
in treated animals or of the drugs or
their metabolites in food products
derived from treated animals.
Products that comply with FDA’s
findings of effectiveness are eligible for
copying, as described in the Generic
Animal Drug and Patent Term
Restoration Act Policy Letter Eight,
August 21, 1991 (56 FR 41561).
Accordingly, sponsors may now obtain
approval of abbreviated NADAs for this
PO 00000 Frm 00032 Fmt 4700 Sfmt 4700 E:\FR\FM\31MRR1.SGM
fixed combination Type A medicated
article and three combination drug
medicated feeds.
The supplemental NADAs are
approved as of February 15, 2006, and
the regulations are amended in 21 CFR
558.76, 558.460, and 558.366, and also
in 21 CFR part 558 by adding new
§ 558.455 to reflect these approvals.
Approval of these supplemental NADAs
did not require review of any new safety
or effectiveness data. Therefore, a
freedom of information summary was
not prepared.
The agency has determined under 21
CFR 25.33(a)(2) that these actions are of
a type that do not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
List of Subjects in 21 CFR Part 558
Animal drugs, Animal feeds.
■ Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 558 is amended as follows:
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
■ 1. The authority citation for 21 CFR
part 558 continues to read as follows:
Authority: 21 U.S.C. 360b, 371.
■ 2. In § 558.76, revise paragraph
(d)(3)(xiii) to read as follows:
§ 558.76 Bacitracin methylene disalicylate.
* * * * *
(d) * * *
(3) * * *
(xiii) Nicarbazin alone or with narasin
or roxarsone or with narasin and
roxarsone as in § 558.366.
* * * * *
■ 3. In § 558.366, amend the table in
paragraph (d) after the entry for
‘‘Narasin 27 to 45 and roxarsone 22.7 to
45.4’’ by adding three entries to read as
follows:
§ 558.366 Nicarbazin.
* * * * *
(d) * * *
31MRR1
 Federal Register / Vol. 71, No. 62 / Friday, March 31, 2006 / Rules and Regulations
Nicarbazin in grams Combination in Indications for use
per ton grams per ton
* * * *
90.8 to 181.6 (0.01 Bacitracin meth- Broiler chickens: As an aid in preventing
to 0.02 pct) ylene disalicy- outbreaks of cecal (Eimeria tenella)
late 4 to 50 and and intestinal (E. acervulina, E. maxi-
roxarsone 22.7 ma, E. necatrix, and E. brunetti) coc-
to 45.4 cidiosis, and for increased rate of
weight gain and improved feed effi-
ciency, and improved pigmentation
Penicillin 2.4 to 50 Broiler chickens: As an aid in preventing
outbreaks of cecal (Eimeria tenella)
and intestinal (E. acervulina, E. maxi-
ma, E. necatrix, and E. brunetti) coc-
cidiosis, and for increased rate of
weight gain and improved feed effi-
ciency
Penicillin 2.4 to 50 Broiler chickens: As an aid in preventing
and roxarsone outbreaks of cecal (Eimeria tenella)
22.7 to 45.4 and intestinal (E. acervulina, E. maxi-
ma, E. necatrix, and E. brunetti) coc-
cidiosis, and for increased rate of
weight gain and improved feed effi-
ciency, and improved pigmentation
* * * *
■ 4. Add § 558.455 to read as follows: oxytetracycline hydrochloride and 50 g/
lb neomycin sulfate or oxytetracycline
§ 558.455 Oxytetracycline and neomycin.
equivalent to 100 g/lb oxytetracycline
(a) Specifications. Type A medicated hydrochloride and 100 g/lb neomycin
articles containing oxytetracycline sulfate.
equivalent to 50 grams per pound (g/lb)
hsrobinson on PROD1PC61 with RULES
VerDate Aug<31>2005 14:51 Mar 30, 2006 Jkt 208001 PO 00000 Frm 00033 Fmt 4700 Sfmt 4700
16225
Limitations Sponsor
* * *
Feed continuously as sole ration from 066104
time chicks are placed on litter until
past the time when coccidiosis is ordi-
narily a hazard; do not use as a treat-
ment for outbreaks of coccidiosis.
Feed as the sole source of organic ar-
senic; drug overdose or lack of water
may result in leg weakness; do not
use in flushing mashes. Discontinue
medication 5 days before marketing
the birds for human consumption to
allow for elimination of the drug from
edible tissue. Do not feed to laying
hens in production. Nicarbazin as pro-
vided by No. 066104; bacitracin meth-
ylene disalicylate and roxarsone by
No. 046573 in § 510.600(c) of this
chapter
Feed continuously as sole ration from 066104
time chicks are placed on litter until
past the time when coccidiosis is ordi-
narily a hazard; do not use as a treat-
ment for outbreaks of coccidiosis. Do
not use in flushing mashes. Do not
feed to chickens producing eggs for
human consumption. Discontinue
medication 5 days before marketing
the birds for human consumption to
allow for elimination of the drug from
edible tissue. Penicillin as procaine
penicillin G. Nicarbazin and penicillin
as provided by No. 066104 in
§ 510.600(c) of this chapter
Feed continuously as sole ration from 066104
time chicks are placed on litter until
past the time when coccidiosis is ordi-
narily a hazard; do not use as a treat-
ment for outbreaks of coccidiosis.
Feed as the sole source of organic ar-
senic; drug overdose or lack of water
may result in leg weakness; do not
use in flushing mashes. Discontinue
medication 5 days before marketing
the birds for human consumption to
allow for elimination of the drug from
edible tissue. Do not feed to laying
hens in production. Penicillin as pro-
caine penicillin G. Nicarbazin and pen-
icillin as provided by No. 066104;
roxarsone by No. 046573 in
§ 510.600(c) of this chapter
* * *
(b) Sponsors. See No. 066104 in
§ 510.600(c) of this chapter.
(c) Related tolerances. See §§ 556.430
and 556.500 of this chapter.
(d) Indications for use—(1) Chickens.
It is used in feed as follows:
E:\FR\FM\31MRR1.SGM 31MRR1
 16226 Federal Register / Vol. 71, No. 62 / Friday, March 31, 2006 / Rules and Regulations

Oxytetracycline and
neomycin sulfate Indications for use Limitations Sponsors
amount in grams
per ton of feed

(i) 10 to 50 Chickens: For increased rate of weight gain and Feed continuously; do not feed to chickens pro- 066104
improved feed efficiency ducing eggs for human consumption

(ii) 100 to 200 Chickens: For control of infectious synovitis Feed continuously for 7 to 14 days (d); do not 066104
caused by Mycoplasma synoviae; control of feed to chickens producing eggs for human
fowl cholera caused by Pasteurella multocida consumption; in low calcium feed, withdraw 3
susceptible to oxytetracycline d before slaughter

(iii) 400 Chickens: For control of chronic respiratory dis- Feed continuously for 7 to 14 d; do not feed to 066104
ease (CRD) and air sac infection caused by chickens producing eggs for human consump-
M. gallisepticum and Escherichia coli suscep- tion; in low calcium feeds, withdraw 3 d be-
tible to oxytetracycline fore slaughter

(iv) 500 Chickens: For reduction of mortality due to air Feed continuously for 5 d; do not feed to chick- 066104
sacculitis (air-sac-infection) caused by E. coli ens producing eggs for human consumption;
susceptible to oxytetracycline withdraw 24 hours before slaughter; in low
calcium feeds withdraw 3 d before slaughter

(2) Turkeys. It is used in feed as

follows:

Oxytetracycline and
neomycin sulfate Indications for use Limitations Sponsors
amount

(i) 10 to 50 g/ton of Growing turkeys: For increased rate of weight Feed continuously; do not feed to turkeys pro- 066104
feed gain and improved feed efficiency ducing eggs for human consumption

(ii) 100 g/ton of Turkeys: For control of hexamitiasis caused by Feed continuously for 7 to 14 d; do not feed to 066104
feed Hexamita meleagridis susceptible to oxytetra- turkeys producing eggs for human consump-
cycline tion

(iii) 200 g/ton of Turkeys: For control of infectious synovitis Feed continuously for 7 to 14 d; withdraw 5 d 066104
feed caused by M. synoviae susceptible to oxytet- before slaughter; do not feed to turkeys pro-
racycline ducing eggs for human consumption

(iv) To provide 25 Turkeys: For control of complicating bacterial or- Feed continuously for 7 to 14 d; withdraw 5 d 066104
mg/lb of body ganisms associated with bluecomb (trans- before slaughter; do not feed to turkeys pro-
weight daily missible enteritis; coronaviral enteritis) sus- ducing eggs for human consumption
ceptible to oxytetracycline

(3) Swine. It is used in feed as follows:

Oxytetracycline and
neomycin sulfate Indications for use Limitations Sponsor
amount

(i) 10 to 50 g/ton of Swine: For increased rate of weight gain and improved feed effi- 066104
feed ciency

(ii) To provide 10 mg/ 1. Swine: For treatment of bacterial enteritis caused by E. coli and Feed continuously for 7 to 066104
lb of body weight Salmonella choleraesuis and treatment of bacterial pneumonia 14 d; withdraw 5 d be-
daily caused by P. multocida susceptible to oxytetracycline; treatment fore slaughter
and control of colibacillosis (bacterial enteritis) caused by E. coli
susceptible to neomycin
2. Breeding swine: For control and treatment of leptospirosis (re- Feed continuously for not 066104
ducing the incidence of abortion and shedding of leptospirae) more than 14 d; with-
caused by Leptospira pomona susceptible to oxytetracycline draw 5 d before slaugh-
ter

(4) Cattle and sheep. It is used in feed

hsrobinson on PROD1PC61 with RULES

as follows:

VerDate Aug<31>2005 14:51 Mar 30, 2006 Jkt 208001 PO 00000 Frm 00034 Fmt 4700 Sfmt 4700 E:\FR\FM\31MRR1.SGM 31MRR1
 Federal Register / Vol. 71, No. 62 / Friday, March 31, 2006 / Rules and Regulations 16227

Oxytetracycline and
neomycin sulfate Indications for use Limitations Sponsor
amount

(i) 10 to 20 grams Sheep: For increased rate of weight 066104

per ton of feed gain and improved feed efficiency

(ii) To provide 0.05 Calves (up to 250 lb): For increased Feed continuously; in milk replacers or starter feed 066104
to 0.1 mg/lb of rate of weight gain and improved
body weight feed efficiency
daily.

(iii) To provide 10 1. Calves and beef and nonlactating
mg/lb of body dairy cattle: For treatment of bacterial
weight daily enteritis caused by E. coli and bac-
terial pneumonia (shipping fever
complex) caused by P. multocida
susceptible to oxytetracycline; treat-
ment and control of colibacillosis
(bacterial enteritis) caused by E. coli
susceptible to neomycin
2. Calves (up to 250 lb): For treatment
of bacterial enteritis caused by E. coli
susceptible to oxytetracycline; treat-
ment and control of colibacillosis
(bacterial enteritis) caused by E. coli
susceptible to neomycin
3. Sheep: For treatment of bacterial en-
teritis caused by E. coli and bacterial
pneumonia caused by P. multocida
susceptible to oxytetracycline; treat-
ment and control of colibacillosis
(bacterial enteritis) caused by E. coli
susceptible to neomycin
Feed continuously for 7 to 14 d; in feed or milk replac- 066104
ers. If symptoms persist after using for 2 or 3 d, con-
sult a veterinarian. Treatment should continue 24 to 48
hours beyond remission of disease symptoms. A with-
drawal period has not been established for use in
preruminating calves. Do not use in calves to be proc-
essed for veal. A milk discard time has not been es-
tablished for use in lactating dairy cattle. Do not use in
female dairy cattle 20 months of age or older. With-
draw 5 d before slaughter
Feed continuously for 7 to 14 d; in milk replacers or 066104
starter feed. If symptoms persist after using for 2 or 3
d, consult a veterinarian. Treatment should continue
24 to 48 hours beyond remission of disease symp-
toms. A withdrawal period has not been established for
use in preruminating calves. Do not use in calves to
be processed for veal. A milk discard time has not
been established for use in lactating dairy cattle. Do
not use in female dairy cattle 20 months of age or
older. Withdraw 5 d before slaughter
Feed continuously for 7 to 14 d. If symptoms persist after 066104
using for 2 or 3 d, consult a veterinarian. Treatment
should continue 24 to 48 hours beyond remission of
disease symptoms. Withdraw 5 d before slaughter

(iv) To provide 25 Calves (250 to 400 lb): For increased 066104

mg/head/day rate of weight gain and improved
feed efficiency

(v) To provide 75 Growing cattle (over 400 lb): For in- 066104
mg/head/day creased rate of weight gain; im-
proved feed efficiency, and reduction
of liver condemnation due to liver ab-
scesses

(vi) To provide 0.5 Cattle: For prevention and treatment of Feed 3 to 5 d before and after arrival in feedlots. A with- 066104
to 2.0 g/head/day the early stages of shipping fever drawal period has not been established for use in
complex preruminating calves. Do not use in calves to be proc-
essed for veal. A milk discard time has not been es-
tablished for use in lactating dairy cattle. Do not use in
female dairy cattle 20 months of age or older

■ 5. In § 558.460, redesignate Dated: March 22, 2006. DEPARTMENT OF HEALTH AND

paragraphs (d)(2)(vi), (d)(2)(vii), and Stephen F. Sundlof, HUMAN SERVICES
(d)(2)(viii) as paragraphs (d)(2)(iii), Director, Center for Veterinary Medicine.
(d)(2)(v), and (d)(2)(vi); and add new Food and Drug Administration
[FR Doc. 06–3120 Filed 3–30–06; 8:45 am]
paragraph (d)(2)(iv) to read as follows: BILLING CODE 4160–01–S
21 CFR Parts 814 and 820
§ 558.460 Penicillin.
* * * * * [Docket No. 2006N–0127]
(d) * * *
Medical Device Reporting; Premarket
(2) * * *
hsrobinson on PROD1PC61 with RULES

Approval of Medical Devices; Quality

(iv) Nicarbazin alone or with System Regulation; Technical
roxarsone as in § 558.366. Amendment
* * * * * AGENCY: Food and Drug Administration,
HHS.

VerDate Aug<31>2005 14:51 Mar 30, 2006 Jkt 208001 PO 00000 Frm 00035 Fmt 4700 Sfmt 4700 E:\FR\FM\31MRR1.SGM 31MRR1